V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20213078 | 20079585 | 1.65 | 67.55 | Palliative (P) | 2019-02-09 | 2019-03-02 | CISPLATIN + FLUOROURACIL + RT | 02 | N | CISPLATIN + FLUOROURACIL | 100811709 |
| 20213080 | 20079586 | 1.55 | 87.4 | Palliative (P) | 2018-03-29 | 2018-04-12 | Cisplatin +Fluorouracil (3 wk) | N | N | CISPLATIN + FLUOROURACIL | 101397610 |
| 20213081 | 20079587 | 1.74 | 111.8 | Palliative (P) | 2017-11-15 | 2017-11-15 | Cisplatin +Fluorouracil (2 wk) | 02 | N | CISPLATIN + FLUOROURACIL | 100646071 |
| 20213082 | 20079588 | 1.8 | 65.7 | Palliative (P) | 2018-04-30 | 2018-05-04 | CISPLATIN + FLUOROURACIL | 02 | N | CISPLATIN + FLUOROURACIL | 100982537 |
| 20213085 | 20079589 | 1.81 | 108.95 | Curative (C) | 2017-10-16 | 2017-10-27 | Trial Unspecified | 01 | Y | TRIAL UNSPECIFIED | 101296337 |
| 20213086 | 20079590 | 1.8 | 84 | Neo-adjuvant (N) | 2017-01-13 | 2017-01-28 | Cisplatin +Fluorouracil (3 wk) | 02 | N | CISPLATIN + FLUOROURACIL | 100208943 |
| 20213088 | 20079592 | 1.7 | 63.9 | Palliative (P) | 2018-03-08 | 2018-03-14 | HCX (Cape + Cisp + Tras) - Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101327690 |
| 20213090 | 20079593 | 1.67 | 55.2 | Curative (C) | 2017-10-17 | 2017-10-22 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101297525 |
| 20213092 | 20079594 | 1.62 | 0 | Palliative (P) | 2020-03-18 | 2020-03-26 | Cape+Cisplatin+Trastuzumab Main | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101647432 |
| 20213093 | 20079595 | 1.69 | 110 | Palliative (P) | 2016-05-22 | 2016-05-22 | Trial Unspecified | Y | N | TRIAL | 101267098 |
| 20213094 | 20079596 | 1.73 | 54.5 | Palliative (P) | 2018-04-19 | 2018-06-07 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 100810244 |
| 20213095 | 20079597 | 0 | 86.3 | null | 2016-09-02 | 2016-09-10 | Imatinib 400mg | 02 | null | IMATINIB | 100174572 |
| 20213096 | 20079598 | 1.72 | 65.25 | Palliative (P) | 2018-05-02 | 2018-05-29 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 100245010 |
| 20213097 | 20079599 | 1.63 | 79.8 | 03 | 2018-04-24 | 2018-05-22 | HCX | 02 | N | IMATINIB | 101481473 |
| 20213098 | 20079600 | 1.66 | 40.8 | Palliative (P) | 2019-12-22 | 2019-12-23 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | TRIAL | 100525011 |
| 20213101 | 20079603 | null | 106 | 03 | 2016-07-03 | 2016-07-08 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | LANREOTIDE | 100965375 |
| 20213102 | 20079604 | 1.72 | 80.7 | Palliative (P) | 2021-12-24 | 2021-12-25 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100569369 |
| 20213104 | 20079606 | 1.77 | null | Palliative (P) | 2019-08-16 | 2019-08-21 | Imatinib 200mg | 02 | N | IMATINIB | 100005440 |
| 20213105 | 20079607 | 1.81 | 78.5 | Curative (C) | 2019-12-19 | 2020-01-11 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100764987 |
| 20213106 | 20079608 | 1.57 | 102 | Curative (C) | 2016-04-21 | 2016-04-21 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101728715 |
| 20213108 | 20079609 | null | 88 | 03 | 2017-08-03 | 2017-09-03 | LANREOTIDE | 02 | N | LANREOTIDE | 100794910 |
| 20213109 | 20079610 | 0 | 116 | Palliative (P) | 2018-07-19 | 2018-07-26 | LANREOTIDE | 02 | N | LANREOTIDE | 100507715 |
| 20213111 | 20079611 | 1.5 | 97.9 | Neo-adjuvant (N) | 2019-11-04 | 2019-11-08 | Trial Unspecified | 01 | N | TRIAL | 101547075 |
| 20213112 | 20079612 | 1.73 | 86 | Palliative (P) | 2017-08-22 | 2017-08-22 | HCX (Cape + Cisp + Tras) - Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100387530 |
| 20213114 | 20079614 | 1.7 | 66.5 | null | 2018-08-05 | 2018-08-23 | IMATINIB | 02 | null | IMATINIB | 100311181 |
| 20213115 | 20079615 | 1.7 | 63.1 | Curative (C) | 2016-03-22 | 2016-03-29 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101614706 |
| 20213116 | 20079616 | 1.72 | 87.3 | Palliative (P) | 2018-09-24 | 2018-09-24 | LANREOTIDE | 02 | N | LANREOTIDE | 100104522 |
| 20213117 | 20079617 | 1.72 | 68.1 | Palliative (P) | 2018-08-23 | 2018-09-02 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101615386 |
| 20213118 | 20079618 | null | null | Palliative (P) | 2016-09-29 | 2016-10-06 | Trial Unspecified | Y | N | TRIAL | 100670051 |
| 20213119 | 20079619 | null | 55 | null | 2019-03-21 | 2019-04-07 | Cape+Cisplatin+Trastuzumab Main | 02 | null | LANREOTIDE | 100711263 |
| 20213120 | 20079620 | 1.77 | 75 | null | 2018-07-25 | 2018-07-25 | IMATINIB | 02 | null | IMATINIB | 101605727 |
| 20213121 | 20079621 | 1.62 | 73.6 | Palliative (P) | 2017-04-24 | 2017-05-08 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101786191 |
| 20213122 | 20079622 | 1.73 | 0 | Palliative (P) | 2016-05-26 | 2016-06-12 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100346548 |
| 20213123 | 20079623 | 1.63 | 79 | Palliative (P) | 2018-07-10 | 2018-07-23 | Imatinib 400mg | N | N | IMATINIB | 101626853 |
| 20213124 | 20079624 | 1.62 | 101 | Palliative (P) | 2016-10-02 | 2016-10-11 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 101361727 |
| 20213125 | 20079625 | 0 | 0 | null | 2020-03-16 | 2020-03-17 | LANREOTIDE | 02 | N | LANREOTIDE | 100223449 |
| 20213127 | 20079627 | 1.6 | 78.4 | Curative (C) | 2017-06-07 | 2017-06-07 | CAPECITABINE + CISPLATIN + Trastuzumab | 01 | Y | FLUOROURACIL + MITOMYCIN + RT | 101443125 |
| 20213128 | 20079628 | 1.58 | 91.4 | null | 2019-09-01 | 2019-09-28 | LANREOTIDE | 02 | null | LANREOTIDE | 101719988 |
| 20213129 | 20079629 | 1.83 | 108.5 | Adjuvant (A) | 2019-02-11 | 2019-02-11 | IMATINIB | 02 | N | IMATINIB | 101865402 |
| 20213130 | 20079630 | 1.92 | 0 | null | 2016-05-21 | 2016-06-06 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 101518676 |
| 20213131 | 20079631 | 1.75 | 49.4 | null | 2018-06-07 | 2018-06-14 | HCX (Cape + Cisp + Tras) - Main | 02 | null | IMATINIB | 100734387 |
| 20213132 | 20079632 | 1.71 | 73.4 | Palliative (P) | 2017-04-13 | 2017-04-25 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101444006 |
| 20213133 | 20079633 | 1.8 | 76 | null | 2018-08-09 | 2018-08-09 | LANREOTIDE | 02 | null | LANREOTIDE | 100628271 |
| 20213134 | 20079634 | 1.73 | 112 | null | 2018-05-12 | 2018-05-30 | Cape+Cisplatin+Trastuzumab Load | 02 | Y | TRIAL | 100707123 |
| 20213135 | 20079635 | 1.68 | 59.78 | Palliative (P) | null | 2017-05-01 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100999093 |
| 20213136 | 20079636 | 1.74 | 61.4 | Palliative (P) | 2017-06-04 | 2017-07-05 | HCX | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100133328 |
| 20213139 | 20079638 | 1.77 | 74.8 | Palliative (P) | 2018-08-09 | 2018-09-05 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101678069 |
| 20213140 | 20079639 | 1.67 | 59 | Curative (C) | 2019-06-25 | 2019-06-25 | FLUOROURACIL + MITOMYCIN + RT | null | Y | FLUOROURACIL + MITOMYCIN + RT | 100454614 |
| 20213142 | 20079640 | null | 69.1 | Palliative (P) | 2018-08-30 | 2018-08-30 | LANREOTIDE | 02 | N | LANREOTIDE | 101024286 |
| 20213143 | 20079641 | 1.59 | 60 | Curative (C) | 2017-05-02 | 2017-05-15 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100024667 |